关键词: 罗格列酮, 急性心肌梗死, 无再流现象, 内皮型一氧化氮合酶

Abstract: Objective To investigate the effect of rosiglitazone on no-reflow and eNOS expression after reperfusion in rats with AMI. Methods Left anterior descending coronary artery was undergone 3 h of occlusion and 2 h of reperfusion to establish the model of no-reflow. 60 SD rats were randomly divided into the control group、the sham operated group、the rosiglitazone group、rosiglitazone plus L-NNA group、L-NNA group; thioflavin-S and Evan's blue were used to delineate the ligation area (LA) and area of no-reflow (ANR); Western blot for phosphorylated eNOS at Ser1177、RT-PCR for mRNA expression of eNOS were performed. Results （1）Compared with control group, area of no-reflow in rosiglitazone group were significantly reduced（P<0.05）, but not in rosiglitazone plus L-NNA group; （2）Compared with the control group，there was no significant differences in mRNA expression of eNOS in rosiglitazone group, whereas Level of p-eNOS Ser1177 protein was significantly increased (P<0.05). Conclusions Rosiglitazone significantly reduced area of no-reflow after reperfusion in rats with AMI, the mechanism of which may be partly due to its role in improving phosphorylation of eNOS, and further increased production of NO.

Key words: Rosiglitazone, Acute myocardial infarction, No-reflow phenomenon, Endothelial nitric oxide synthase